A valuation of infusion therapy to preserve islet function in type 1 diabetes

Value in Health

Volumn 13, Issue 5, 2010, Pages 636-642

  Lloyd, Andrew ^a   Swinburn, Paul ^a   Boye, Kristina S ^b   Curtis, Bradley ^b   Sarpong, Eric ^b   Goldsmith, Kim ^c   Bode, Bruce ^d   Aronoff, Stephen ^e  

^a ICON PLC   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d ATLANTA DIABETES ASSOCIATES   (United States)

^e Endocrine Associates of Dallas   (United States)

Author keywords

quality of life; teplizumab; type 1 diabetes; utility

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ADOLESCENT; ADULT; ARTICLE; BIOMETRY; CHILD; FEMALE; HEALTH STATUS; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; OUTCOME ASSESSMENT; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; SELF REPORT; TREATMENT OUTCOME; UNITED KINGDOM;

EID: 76249131486     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00705.x     Document Type: Article

References (27)

1. DCCT Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993 329 : 977 986.
2. EDIC Group Epidemiology of diabetes interventions and complications (edic). design, implementation, and preliminary results of a long-term follow-up of the diabetes control and complications trial cohort. Diabetes Care 1999 22 : 99 111.
3. Hahl J, Hämäläinen H, Sintonen H, et al. Health-related quality of life in type 1 diabetes without or with symptoms of long-term complications. Qual Life Res 2002 11 : 427 436.
4. Brown WM. Anti-CD3 antibody Macrogenics Inc. Curr Opin Investig Drugs 2006 7 : 381 388.
5. Food & Drug Administration Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutics Biologics for Treatment and Prevention, 2008. Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf [Accessed July 30, 2010 JH, Yamamura A, et al. Improvement of glycemic control and quality-of-life by insulin lispro therapy: assessing benefits by ITR-QOL questionnaires. Diabetes Res Clin Pract 2008 81 : 169 178.
6. National Institute of Clinical Excellence (NICE). Guide to Methods of Health Technology Assessment. London, UK : NICE, 2004.
7. Kostopoulou O. The transient nature of utilities and health preferences. Med Decis Making 2006 26 : 304 306.
8. Sato E, Ohsawa I, Kataoka J, et al. Socio-psychological problem of patients with late adolescent onset type 1 diabetes - analysis by qualitative research. Nagoya J Med Sci 2003 66 : 21 9.
9. Debono M, Cachia E. The impact of diabetes on psychological well being and quality of life. The role of patient education. Psychol Health Med 2007 12 : 545 555.
10. Rendeli C, Padua L, Ausili E, et al. Quality of life in young diabetic patients. Diabetes Nutr Metab 2003 16 : 251 256.
11. Hislop AL, Fegan PG, Schlaeppi MJ, et al. Prevalence and associations of psychological distress in young adults with Type 1 diabetes. Diabet Med 2007 25 : 91 6.
12. Faulkner MS. Quality of life for adolescents with type 1 diabetes: parental and youth perspectives. Pediatr Nurs 2003 29 : 362 368.
13. de Wit M, Delemarre-van de waal HA, Bokma JA, et al. Self-report and parent-report of physical and psychosocial well-being in Dutch adolescents with type 1 diabetes in relation to glycaemic control. Health Qual Life Outcomes 2007 5 : 10.
14. Vanelli M, Chiarelli F, Chiari G, Tumini S. Relationship between metabolic control and quality of life in adolescents with type 1 diabetes. Acta Biomed 2003 1 : 13 7.
15. Hassan K, Loar R, Anderson BJ, Heptulla RA. The role of socioeconomic status, depression, quality of life, and glycaemic control in type 1 diabetes mellitus. J Pediatr 2006 149 : 526 531.
16. Hoey H, Aanstoot HJ, Chiarelli F, et al. Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes. Diabetes Care 2001 23 : 1923 1928.
17. Ausili E, Tabacco F, Focarelli B, et al. Multidimensional study on quality of life in children with type 1 diabetes. Eur Rev Med Pharmacol Sci 2007 11 : 249 255.
18. Wagner VM, Müller-Godeffroy E. Age, metabolic control and type of insulin regime influences health-related quality of life in children and adolescents with type 1 diabetes. Eur J Pediatr 2005 164 : 491 496.
19. Graue M, Wentzel-Larsen T, Hanestad BR, Søvik O. Health-related quality of life and metabolic control in adolescents with diabetes: the role of parental care, control and involvement. J Pediatr Nurs 2005 20 : 373 382.
20. Weijman I, Ros WJ, Rutten GE, et al. Frequency and perceived burden of diabetes self-management activities in employees with insulin-treated diabetes: relationships with health outcomes. Diabetes Res Clin Pract 2005 68 : 56 64.
21. Nordfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycaemia in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2005 18 : 83 91.
22. Joffe H, Yardley L. Content and thematic analysis. In : Marks D, Yardley L, eds., Research Methods for Clinical and Health Psychology. London : Sage, 2004.
23. Brooks R. EuroQol: the current state of play. Health Policy 1996 37 : 53 72.
24. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 33 : 337 343.
25. Dolan P. Modeling valuations for EuroQoL health states. Med Care 1997 35 : 1095 1106.
26. Gonder-Frederick L, Cox D. Hypoglycemia Fear Survey - 1998 Version. Charlotteville: University of Virginia, 1998.
27. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986 5 : 1 30.